Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-06-18
1999-03-02
Stockton, Laura L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
544176, 548131, 558401, 560101, 562491, 564 74, 564181, 564265, 564305, 514364, 514532, 514520, 514570, A61K 31165, C07C23300
Patent
active
058772197
ABSTRACT:
Described herein are non-steroidal ligands for the estrogen receptor which possess tissue-dependent estrogenic and antiestrogenic activity as well as methods for making the same and their applications in treating a variety of disease states.
REFERENCES:
patent: 3341537 (1967-09-01), Richardson et al.
patent: 3367856 (1968-02-01), Landquist et al.
patent: 3493606 (1970-02-01), Richardson et al.
patent: 4198435 (1980-04-01), Richardson et al.
patent: 4206234 (1980-06-01), Richardson et al.
patent: 4307111 (1981-12-01), Crawley
patent: 4536516 (1985-08-01), Harper et al.
patent: 4623660 (1986-11-01), Richardson
patent: 4803227 (1989-02-01), Brandes et al.
patent: 4851433 (1989-07-01), Kraus
patent: 4859695 (1989-08-01), McKissick et al.
patent: 4894373 (1990-01-01), Young
patent: 4960937 (1990-10-01), Woschina et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5393785 (1995-02-01), Labrie et al.
patent: 5681835 (1997-10-01), Willson
Robertson et al., "Antiestrogen Basicity-Activity Relationships: A Comparison of the Estrogen Receptor Binding and Antiuterotropic Potencies phenyl!-1-butene (Tamoxifen, Nolvadex) Having Altered Basicity", J. Med. Chem. 25, pp. 167-171 (1982).
Jordan et al., "Endocrine Pharmacology of Antiestrogens as Antitumor Agents", Endocrine Reviews, vol. 11, No. 4, pp. 578-610 (1990).
Lerner et al., "Development of antiestrogens and their use in breast cancer: eighth Cain Memorial Award Lecture", Cancer Research, 50:4177, Jul. 15, 1990.
Jordan et al., "Structural requirements for the pharmacological activity of non-steroidal antiestrogens in vitro", Mol. Pharm., 26:272 (1984).
Jordan et al., "A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity", J. Endocrinol 75:305 (1977).
Jordan et al. "Importance of the alkylaminoethyoxy side chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifen in the immature rat uterus" Mol. Cell Endocrinol, 27:291 (1982).
Jarmen et al., "Analogues of tamoxifen: the role of the basic side chain. Applications of a whole cell oestrogen-receptor binding assay to N-oxides and Quanternery salts." AntiCancer Drug Design, 1:259 (1986).
Murphy et al., Structural components necessary for the antiestrogenic activity of tamoxifen:, J. Steroid Biochem, 34:407 (1989).
Harper et al., "Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes", Nature, 212:87 (1966).
Jordan et al., "Geometric isomers of substituted triphenylenes and antiestrogen action", Endocrinology, 108:1353, 1981.
Katzenellenbogen et al., "Bioactivities, estrogen receptor interactions and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells", Center Res. 44:112 (1984).
Katzenellenbogen et al., "Facile geometric isomerization of phenolic nonsteroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers", J. Steroid Biochem, 22:589 (1985).
McCague et al., "Synthesis and estrogen receptor binding of ethoxy!phenyl!5H-benzocyclo-heptene, a non-isomerizable analogue of tamoxifen", X-Ray Crystallographic Studies, J. Med Chem, 29:2053 (1986).
McCague et al., "Non-isomerizable analogues of (Z)- and - (E)-4 hydroxytamoxifen." Synthesis and endocrinological properties of subsituted diphenylbezocycloheptenes, J. Med Chem, 31:1285 (1988).
McCague et al., "Non-isomerizable antiestrogens related to tamoxifen", J. Steroid Biochem, 31:545 (1988).
Katzenellenbogen et al., "Efficient and highly selective covalent labeling Chem, 258:3487 (1983).
Harlow et al., "Identification of crystein-530 as the covalent attachment site of an affinity labeling estrogen (ketonoestrolaziridine) and antiestrogen (tamoxifenaziridine) on the human estrogen receptor"m J. Biol Chem, 264:17476(1989).
Lees et al., "Identification of two transactivation domains in the mouse oestrogen receptor", Nucleic Acids Res., 17:5477 (1989).
Fawell et al., "Inhibition of estrogen receptor-DNA binding by the `pure` antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization", Proc. Natl. Acad Sci USA, 87:6883 (1990).
Love et al., "Bone mineral density in women with breast cancer treated for at least t wo years with Tamoxifen", Breast Cancer Res. Treat., 12:297 (1988).
Turken et al., Effects of Tamoxifen on spinal bone density in women with breast density women with breast cancer, J. Natl. Cancer Inst., 81:1086 (1989).
Fentiman et al., "Bone mineral content of women receiving tamoxifen for mastalgia", Br. J. Cancer, 60:262 (1989).
Fornander et al., "Long-term adjuvent tamoxifen in early breast cancer: effect on bone mineral denisty in postmenopausal women", J. Clin. Oncol, 8:1019 (1990).
Rossner et al., "Serum lipoproteins after breast cancer surgery and effects of tamoxifen", Atherosclerosis, 53:339 (1984).
Bruning et al., "Serum lipoproteins and cardiovascular risk", Br. J. Cancer, 58:497 (1988).
Bertelli et al., "Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels", Breast Cancer Res. Treat., 12:307 (1988).
Caleffi et al., "Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain", J. Endocrinol, 199:335 (1988).
Bagdade et al., "Effect of tamoxifen treatment on plasma lipids and lipoproteins lipid composition", J. Clin Endocrinol Metab, 70:1132 (1990).
Love et al., "Effects of Tamoxifen Therapy on Lipid and lipoprotein levels in postmenapausal patients with node negative breast cancer", JNCI, 82:1327 (1990).
McCague et al., "Derivatives of Tamoxifen, Dependence of Antiestrogenicity on the 4-Substituent", J. Med Chem, vol. 32, pp. 2527-2533 (1989).
Duax et al., "Structral Features which distinguish estrogen agonists and antagonists", J. Steroid Biochem, vol. 27, pp. 271-280 (1987).
Willson, Timothy M. et al. Journal of Medicinal Chemistry, "3-(4(1,2-Diphenylbut-1-cnyl)phenyl acylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats.", vol. 37, No. 11, May 27, 1994, Washington.
Gradishar et al., Journal of Clinical Oncology, Feb. 1997, vol. 15, No. 2, pp. 840-852.
Dadswell Chuck E.
Glaxo WellcomeInc.
Harrington R. Cole
Stockton Laura L.
LandOfFree
Non-steroidal ligands for the estrogen receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-steroidal ligands for the estrogen receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-steroidal ligands for the estrogen receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423415